SCRIP
CITELINE COMMERCIAL

24 Jul 2022 | **News**

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen's growth challenges; Novartis's view on large M&A; pharma's Q2 outlook; and MSD on Lagevrio.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 22 July 2022, including: *Novo Nordisk A/S* obesity drugs in US cost-effectiveness spotlight; *Biogen, Inc.*'s growth challenges; *Novartis AG*'s view on large M&A; pharma's Q2 outlook; and *MSD* on Lagevrio.

This and all our other podcasts are available on the Pharma Intelligence channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud*, *TuneIn* and *Spotify Podcasts*, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*Novo Nordisk's Obesity Drugs Exceed ICER's Cost Effectiveness Thresholds*" - Scrip, 18 Jul, 2022.)

(Also see "*Without An Alzheimer's Blockbuster, Biogen Is A Ship Without A Growth Rudder*" - Scrip, 20 Jul, 2022.)

(Also see "*Novartis Finance Chief Rules Out Large M&A*" - Scrip, 19 Jul, 2022.)

(Also see "*Pharma Q2 Preview: Demonstrating Resiliency Against A Turbulent Backdrop*" - Scrip, 15 Jul, 2022.)

(Also see "*MSD's Asia Pacific Chief On Lagevrio's Gains In Clinical Utility Amid Paxlovid Luster*" -

© Citeline 2024. All rights reserved.

SCRIP
CITELINE COMMERCIAL

Scrip, 19 Jul, 2022.)

Click here to explore this interactive content online

© Citeline 2024. All rights reserved.